<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01630057</url>
  </required_header>
  <id_info>
    <org_study_id>E2090-E039-401</org_study_id>
    <nct_id>NCT01630057</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug</brief_title>
  <official_title>An Open-label, Randomized, Multi-centre, Superiority Study to Compare, in Patients With Partial Onset Seizures, the Efficacy and Safety of Adjunctive Zonisamide vs Replacement With Zonisamide of the Last Added Antiepileptic Drug</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open-label, randomized, multi-centre, superiority study to assess that, in patients who
      respond to zonisamide added as third drug after failure of a two-drug combination therapy,
      the triple therapy is superior to the conversion to a double therapy including zonisamide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events as a Measure of Safety and Tolerability in patients who respond to zonisamide added as third drug after failure of a two-drug combination therapy</measure>
    <time_frame>13 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Partial Seizures</condition>
  <arm_group>
    <arm_group_label>Adjunctive Zonisamide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Replacement with Zonisamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will continue to receive zonisamide as third drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adjunctive Zonisamide</intervention_name>
    <description>Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.</description>
    <arm_group_label>Adjunctive Zonisamide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Replacement with Zonisamide</intervention_name>
    <description>Patients will continue to receive zonisamide as third drug</description>
    <arm_group_label>Replacement with Zonisamide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with localization-related epilepsy, who have added a second drug to the
        monotherapy, haven't obtained an adequate reduction of seizure frequency with this
        combination and have responded to zonisamide added as third drug for at least three months.

        Inclusion criteria:

          -  Age â‰¥ 18 years;

          -  Patients with non progressive localization-related epilepsy;

          -  Patients who are able and willing to give written Informed Consent;

          -  Current treatment with three antiepileptic drugs. The last antiepileptic drug
             introduced must be zonisamide;

          -  50% or greater seizure reduction* as assessed after an at least three-month
             maintenance period with zonisamide.

               -  = seizure frequency before starting zonisamide must be documented checking case
                  histories.

        Exclusion criteria:

          -  Patients contraindicated for zonisamide use (see SmPC);

          -  Patients with renal or hepatic impairment;

          -  Pregnant or lactating women;

          -  Women of childbearing age who are not willing to use any contraceptive method with
             established efficacy.

          -  Patients suffering from clinically significant psychiatric illness, psychological or
             behavioral problems which could interfere with study participation;

          -  Patients with a history (within the last 12 months) of alcohol or drug abuse or
             dependency;

          -  Patients who have been on an investigational drug or device within 30 days prior to
             the initiation of the present study;

          -  Patients with a documented computed axial tomography (CAT) scan or magnetic resonance
             imaging (MRI) scan confirming the presence of a progressive neurological lesion within
             12 months of the screening visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Striano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Azienda Ospedaliera Universitaria Federico II</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AOU Ospedali riuniti Umberto I -G.M Lancisi-G.Salesi</name>
      <address>
        <city>Ancona</city>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Universitaria Consorziale Policlinico di Bari</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs &quot;E. Medea&quot;</name>
      <address>
        <city>Bosisio Parini</city>
        <zip>23842</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Struttura di Neurofisiopatologia, Universit? degli studi di Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>09124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS &quot;Eugenio Medea&quot; Polo Scientifico di Conegliano</name>
      <address>
        <city>Conegliano</city>
        <zip>31015</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AOU di Ferrara Arcispedale S. Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedale &quot;S.Antonio Abate di Gallarate&quot;</name>
      <address>
        <city>Gallarate</city>
        <zip>21013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UOC Neurofisiopatologia PO S. Salvatore</name>
      <address>
        <city>L'Aquila</city>
        <zip>67100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO della Provincia di Lodi</name>
      <address>
        <city>Lodi</city>
        <zip>26900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Centro neurolesi &quot;Bonino Pulejo&quot; di Messina</name>
      <address>
        <city>Messina</city>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO di Rilievo Nazionale Antonio Cardarelli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Universitaria Federico II</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Universitaria Policlinico Paolo Giaccone dell'Universit? degli Studi di Palermo</name>
      <address>
        <city>Palermo</city>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Universitaria -Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AO Regionale &quot;San Carlo&quot; di Potenza</name>
      <address>
        <city>Potenza</city>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PO &quot;Misericordia e dolce&quot;-USL 4 di Prato</name>
      <address>
        <city>Prato</city>
        <zip>59100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Complesso Ospedaliero San Filippo Neri</name>
      <address>
        <city>Roma</city>
        <zip>00135</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umberto I Policlinico di Roma</name>
      <address>
        <city>Roma</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale SS Giovanni e Paolo Azienda ULSS 12 Veneziana</name>
      <address>
        <city>Venezia</city>
        <zip>30174</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2012</study_first_posted>
  <last_update_submitted>July 11, 2014</last_update_submitted>
  <last_update_submitted_qc>July 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Anticonvulsants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

